Anti-LHPL3/ LHFPL3/ LHFPL4 monoclonal antibody

Anti-LHPL3/ LHFPL3/ LHFPL4 antibody for FACS & in-vivo assay

Target products collectionGo to LHFPL3/LHFPL3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0728-Ab-1/ GM-Tg-hg-MP0728-Ab-2Anti-Human LHFPL3 monoclonal antibodyHuman
GM-Tg-rg-MP0728-Ab-1/ GM-Tg-rg-MP0728-Ab-2Anti-Rat LHFPL3 monoclonal antibodyRat
GM-Tg-mg-MP0728-Ab-1/ GM-Tg-mg-MP0728-Ab-2Anti-Mouse LHFPL3 monoclonal antibodyMouse
GM-Tg-cynog-MP0728-Ab-1/ GM-Tg-cynog-MP0728-Ab-2Anti-Cynomolgus/ Rhesus macaque LHFPL3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0728-Ab-1/ GM-Tg-felg-MP0728-Ab-2Anti-Feline LHFPL3 monoclonal antibodyFeline
GM-Tg-cang-MP0728-Ab-1/ GM-Tg-cang-MP0728-Ab-2Anti-Canine LHFPL3 monoclonal antibodyCanine
GM-Tg-bovg-MP0728-Ab-1/ GM-Tg-bovg-MP0728-Ab-2Anti-Bovine LHFPL3 monoclonal antibodyBovine
GM-Tg-equg-MP0728-Ab-1/ GM-Tg-equg-MP0728-Ab-2Anti-Equine LHFPL3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0728-Ab-1/ GM-Tg-hg-MP0728-Ab-2; GM-Tg-rg-MP0728-Ab-1/ GM-Tg-rg-MP0728-Ab-2;
GM-Tg-mg-MP0728-Ab-1/ GM-Tg-mg-MP0728-Ab-2; GM-Tg-cynog-MP0728-Ab-1/ GM-Tg-cynog-MP0728-Ab-2;
GM-Tg-felg-MP0728-Ab-1/ GM-Tg-felg-MP0728-Ab-2; GM-Tg-cang-MP0728-Ab-1/ GM-Tg-cang-MP0728-Ab-2;
GM-Tg-bovg-MP0728-Ab-1/ GM-Tg-bovg-MP0728-Ab-2; GM-Tg-equg-MP0728-Ab-1/ GM-Tg-equg-MP0728-Ab-2
Products NameAnti-LHFPL3 monoclonal antibody
Formatmab
Target NameLHFPL3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LHFPL3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LHPL3/ LHFPL3/ LHFPL4 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0728
    Target NameLHFPL3
    Gene ID375612,269629,103692025,697053,119864179,105260374,520147,100058820
    Gene Symbol and SynonymsA930031L14Rik,LHFPL3,LHFPL4,RGD1559727
    Uniprot AccessionQ86UP9
    Uniprot Entry NameLHPL3_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000187416
    Target ClassificationN/A

    The target: LHFPL3, gene name: LHFPL3, also named as LHFPL4. This gene is a member of the lipoma HMGIC fusion partner (LHFP) gene family, which is a subset of the superfamily of tetraspan transmembrane protein encoding genes. Mutations in one LHFP-like gene result in deafness in humans and mice, and a second LHFP-like gene is fused to a high-mobility group gene in a translocation-associated lipoma. A partial gene fragment named LHFPL4 corresponds to a portion of the first exon of this gene. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.